282 related articles for article (PubMed ID: 8611378)
1. Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phe1-octreotide.
Wangberg B; Forssell-Aronsson E; Tisell LE; Nilsson O; Fjalling M; Ahlman H
Br J Cancer; 1996 Mar; 73(6):770-5. PubMed ID: 8611378
[TBL] [Abstract][Full Text] [Related]
2. Radioisotope-guided surgery in patients with neuroendocrine tumours.
Ahlman H
Digestion; 1996; 57 Suppl 1():88-9. PubMed ID: 8813480
[TBL] [Abstract][Full Text] [Related]
3. A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.
Breeman WA; Hofland LJ; van der Pluijm M; van Koetsveld PM; de Jong M; Setyono-Han B; Bakker WH; Kwekkeboom DJ; Visser TJ; Lamberts SW
Eur J Nucl Med; 1994 Apr; 21(4):328-35. PubMed ID: 7911760
[TBL] [Abstract][Full Text] [Related]
4. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging.
Shi W; Johnston CF; Buchanan KD; Ferguson WR; Laird JD; Crothers JG; McIlrath EM
QJM; 1998 Apr; 91(4):295-301. PubMed ID: 9666953
[TBL] [Abstract][Full Text] [Related]
5. Indium-111 activity concentration in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-1-octreotide.
Forssell-Aronsson E; Fjälling M; Nilsson O; Tisell LE; Wängberg B; Ahlman H
J Nucl Med; 1995 Jan; 36(1):7-12. PubMed ID: 7799086
[TBL] [Abstract][Full Text] [Related]
6. 111In-labelled octreotide binding by the somatostatin receptor subtype 2 in neuroendocrine tumours.
Hashemi SH; Benjegård SA; Ahlman H; Wängberg B; Forssell-Aronsson E; Billig H; Nilsson O
Br J Surg; 2003 May; 90(5):549-54. PubMed ID: 12734860
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide.
Westlin JE; Janson ET; Arnberg H; Ahlström H; Oberg K; Nilsson S
Acta Oncol; 1993; 32(7-8):783-6. PubMed ID: 8305227
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of octreotide scintigraphy in patients with midgut carcinoid tumours and evaluation of intraoperative scintillation detection.
Ahlman H; Wängberg B; Tisell LE; Nilsson O; Fjälling M; Forssell-Aronsson E
Br J Surg; 1994 Aug; 81(8):1144-9. PubMed ID: 7953343
[TBL] [Abstract][Full Text] [Related]
9. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
Bangard M; Béhé M; Guhlke S; Otte R; Bender H; Maecke HR; Biersack HJ
Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
[TBL] [Abstract][Full Text] [Related]
10. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H
Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822
[TBL] [Abstract][Full Text] [Related]
11. Intraoperative tumour detection using 111In-DTPA-D-Phe1-octreotide and a scintillation detector.
Benjegård SA; Forssell-Aronsson E; Wängberg B; Skånberg J; Nilsson O; Ahlman H
Eur J Nucl Med; 2001 Oct; 28(10):1456-62. PubMed ID: 11685487
[TBL] [Abstract][Full Text] [Related]
12. [Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors].
Eising EG; Farahati J; Bier D; Knust EJ; Reiners C
Nuklearmedizin; 1995 Feb; 34(1):1-7. PubMed ID: 7724358
[TBL] [Abstract][Full Text] [Related]
13. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors.
Janson ET; Westlin JE; Ohrvall U; Oberg K; Lukinius A
J Nucl Med; 2000 Sep; 41(9):1514-8. PubMed ID: 10994731
[TBL] [Abstract][Full Text] [Related]
14. Use of an isotopic somatostatin receptor probe to image gut endocrine tumors.
Modlin IM; Cornelius E; Lawton GP
Arch Surg; 1995 Apr; 130(4):367-73; discussion 373-4. PubMed ID: 7710334
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin receptors on neuroendocrine tumors--a way to intraoperative diagnosis and localization.
Ahlman H; Tisell LE; Wängberg B; Nilsson O; Fjälling M; Forssell-Aronsson E
Yale J Biol Med; 1994; 67(3-4):215-21. PubMed ID: 7502530
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin receptor imaging in patients with neuroendocrine tumors: preoperative and postoperative scintigraphy and intraoperative use of a scintillation detector.
Ahlman H; Tisell LE; Wängberg B; Nilsson O; Forssell-Aronsson E; Fjälling M
Semin Oncol; 1994 Oct; 21(5 Suppl 13):21-8. PubMed ID: 7992076
[No Abstract] [Full Text] [Related]
17. Somatostatin receptor: scintigraphy and radionuclide therapy.
Krenning EP; Kooij PP; Pauwels S; Breeman WA; Postema PT; De Herder WW; Valkema R; Kwekkeboom DJ
Digestion; 1996; 57 Suppl 1():57-61. PubMed ID: 8813472
[TBL] [Abstract][Full Text] [Related]
18. Indium-111-octreotide scintigraphy, intraoperative gamma-detector localisation and somatostatin receptor expression in primary human breast cancer.
Skånberg J; Ahlman H; Benjegård SA; Fjälling M; Forssell-Aronsson EB; Hashemi SH; Nilsson O; Suurkula M; Jansson S
Breast Cancer Res Treat; 2002 Jul; 74(2):101-11. PubMed ID: 12186370
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of somatostatin receptor scintigraphy.
Kwekkeboom DJ; Lamberts SW; Habbema JD; Krenning EP
J Nucl Med; 1996 Jun; 37(6):886-92. PubMed ID: 8683305
[TBL] [Abstract][Full Text] [Related]
20. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.
Anderson CJ; Dehdashti F; Cutler PD; Schwarz SW; Laforest R; Bass LA; Lewis JS; McCarthy DW
J Nucl Med; 2001 Feb; 42(2):213-21. PubMed ID: 11216519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]